Shreekant Parasuraman, BPharm, PhD
Authored Items
Andrew Bai, MS, Ruben A. Mesa, MD, FACP, Dilan Paranagama, PhD, Shreekant Parasuraman, BPharm, PhD, Jingbo Yu, PhD
November 14, 2017 | November 2017 Vol 8, No 11
The MPNs myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are associated with a variety of burdensome symptoms (BMC Cancer. 2016;16:167) and reduced survival compared with the general population (PLOS One. 2014;9:e90299).
Last modified: June 5, 2018